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Background: Current staging systems for cutaneous squamous cell carcinoma (cSCC) 74 
have limited positive predictive value (PPV) for identifying patients who will experience 75 
metastasis. 76 
Objective: To develop and validate a gene expression profile (GEP) test for predicting 77 
risk for metastasis in localized, high-risk cSCC with the goal of improving risk-directed 78 
patient management. 79 
Methods: Archival formalin-fixed paraffin-embedded primary cSCC tissue and 80 
clinicopathologic data (n=586) were collected from 23 independent centers in a 81 
prospectively designed study. A GEP signature was developed using a discovery cohort 82 
(n=202) and validated in a separate, non-overlaping, independent cohort (n=324).   83 
Results: A prognostic, 40-gene expression profile (40-GEP) test was developed and 84 
validated, stratifying high-risk cSCC patients into classes based on metastasis risk: 85 
Class 1 (low-risk), Class 2A (high-risk), and Class 2B (highest-risk). For the validation 86 
cohort, 3-year metastasis-free survival (MFS) rates were 91.4%, 80.6%, and 44.0%, 87 
respectively. A PPV of 60% was achieved for the highest-risk group (Class 2B), an 88 
improvement over staging systems; while negative predictive value, sensitivity, and 89 
specificity were comparable to staging systems.  90 
Limitations: Potential understaging of cases could affect metastasis rate accuracy. 91 
Conclusion: The 40-GEP test is an independent predictor of metastatic risk that can 92 




Keywords: cutaneous squamous cell carcinoma; gene expression profile; prognostication; 95 
metastasis; risk 96 
 97 
Capsule Summary: 98 
• Development and independent validation of a 40-gene expression profile (40-99 
GEP) test demonstrated improved metastasis risk stratification of patients with 100 
high-risk cutaneous squamous cell carcinoma (cSCC). 101 
• Incorporation of 40-GEP prognostication into clinical practice could support risk-102 
aligned patient management decisions by complementing current staging 103 
systems. 104 
 105 





Incidence of cutaneous squamous cell carcinoma (cSCC) has increased 109 
substantially in recent decades,1, 2 with concurrent increases in morbidity and mortality. 110 
Currently, estimated cSCC incidence ranges from 1 to 2.5 million cases annually in the 111 
US,2–5 and deaths from cSCC are estimated to exceed deaths from melanoma.2, 4–11 112 
The rates of metastasis of tumors with high-risk features can surpass 20%.3, 10, 12–19 113 
Once metastasis is detected, 5-year survival rates drop to 50-83% and <40% for 114 
patients with regional and distant metastasis, respectively.16, 20–22 Since early detection 115 
of metastasis is correlated with better outcomes, accurate identification of patients at 116 
high risk for metastasis is critical, potentially allowing for early adjuvant therapy, while 117 
also avoiding overtreatment of low-risk tumors.   118 
Clinicopathologic staging and national guidelines are used to risk-stratify and 119 
manage patients. National Comprehensive Cancer Network (NCCN) guidelines assign 120 
patients with local disease to low- and high-risk groups using clinicopathologic features 121 
associated with recurrence, providing broad recommendations for surgical and 122 
therapeutic interventions.3 The American Joint Committee on Cancer (AJCC) Staging 123 
Manual uses clinicopathologic features of the primary tumor with four T-stages grouped 124 
into binary risk groups (T1-T2 vs. T3-T4).23 Positive predictive value (PPV) is low for 125 
NCCN and AJCC (14%–17%),24–27 as many patients categorized as high risk do not 126 
develop advanced disease.28, 29 The Brigham and Women’s Hospital (BWH) staging 127 
system includes four T-stages (T1, T2a, T2b, and T3) categorizing tumors by number of 128 
high-risk features observed. For BWH, T2b-T3 tumors are generally combined to 129 
 
 
identify “high-risk” disease. Sensitivity is comparable between BWH and AJCC, while 130 
PPV for BWH (24%-38%) is superior to AJCC.24–27  131 
 To improve identification of patients with primary cSCC at high risk for metastatic 132 
disease, a 40-gene expression profile (40-GEP) test was developed. Gene expression 133 
profiling (GEP) of primary cSCC tumors with known outcomes was used to develop a 134 
prognostic molecular algorithm. We report validation of this 40-GEP test which identifies 135 
three classes (Class 1, 2A, and 2B) of cSCC patients with different likelihood of 136 
developing metastasis within 3 years of diagnosis. The 40-GEP test is an independent 137 
predictor of outcomes and improves upon risk prediction with staging systems, 138 
supporting its potential clinical use in conjunction with standard staging and patient 139 
management criteria.    140 
 141 
Methods 142 
Study Design 143 
A prospectively-designed biomarker study was conducted using archival primary 144 
cSCC formalin-fixed paraffin-embedded tissue. The primary endpoint was 3-year 145 
metastasis-free survival (MFS), including regional and distant metastatic events. 146 
Regional metastasis was defined as metastasis within the regional nodal basin, 147 
including satellite or in-transit metastasis, but excluding local recurrence. Distant 148 
metastasis was defined as metastasis beyond the regional lymph node basin. Disease-149 
specific death, a secondary endpoint, was defined as documented death from cSCC. All 150 
cases included in the study were primary cSCC tumors (Figure 1).  Cases with local 151 
recurrence only were not considered as having a metastatic event. 152 
 
 
Expression of 140 candidate genes, identified by discovery efforts or literature 153 
review30–36, was determined for samples in the discovery and development cases 154 
(cohort 1, n=202). Deep machine learning was applied to expression data from 122 155 
genes passing initial expression thresholds to select genes for further signature training. 156 
See Data Supplement for detailed methods of discovery/development. The algorithm 157 
encompassing the 40-GEP assay was selected based on prognostic performance in the 158 
training cases (n=122). Coefficients for each gene in the algorithm were locked prior to 159 
validation. Power calculations indicated that the validation cohort (cohort 2, samples 160 
passing QC, n=321) could detect a hazard ratio (HR) of 2.1 for metastasis (90% power, 161 
alpha=0.05). After validation of the algorithm using cohort 2, clinically actionable 162 
cutpoints for probability scores were set to optimize negative predictive value (NPV), 163 
PPV, and sensitivity for metastasis risk groups (Class 1: low-risk, Class 2A: high-risk, 164 
Class 2B: highest-risk). 165 
Patient Enrollment and Specimen Acquisition  166 
Primary cSCC tissue and associated de-identified clinical data were obtained 167 
from 23 independent centers following Institutional Review Board approval. 168 
Clinicopathological and outcomes data were entered into a secure case report form. All 169 
reported patient data were monitored on-site, including review of all available pathology 170 
reports and medical records. Per the ongoing study protocol, 586 archival cSCC cases 171 
were received between the study onset (September 3, 2016) and October 1, 2019 172 
(Figure 1). Complete protocol inclusion/exclusion criteria are summarized in the Data 173 
Supplement. The protocol targeted enrollment of cases with at least one high-risk 174 
feature as defined by NCCN guidelines or by AJCC or BWH staging >T1, either at the 175 
 
 
patient or tumor level, to model the high-risk cSCC patient population for whom the 40-176 
GEP assay was developed. For the validation cohort, monitors reviewed 98.4% 177 
(314/319) of all definitive surgery pathology reports. Staging incorporated all available 178 
data in the medical record and centralized pathology review by a board-certified 179 
dermatopathologist.  180 
Assay Methods and Statistical Analyses 181 
Tissue sections (5µm) were freshly cut at contributing institutions and collected at 182 
a central CAP-accredited laboratory. Tumor tissue, including tumor stroma, was 183 
macrodissected from slides and processed to generate RNA and cDNA as previously 184 
described.37 cDNA underwent a 14-cycle preamplification step prior to dilution, and then 185 
was mixed 1:1 with 2x TaqMan Gene Expression Master Mix. Quantitative PCR was 186 
then performed using high-throughput microfluidics gene cards containing primers 187 
specific to the genes of interest and the QuantStudio 12K Flex Real-Time PCR System 188 
(Life Technologies). Each sample was run in triplicate with randomization onto plates to 189 
distribute metastatic and nonmetastatic cases. Laboratory personnel and clinical 190 
monitoring staff were blinded to GEP results during data capture. Statistical analysis 191 
was performed as previously described using standard methods for Kaplan-Meier 192 
analysis, multivariable Cox regression analysis, accuaracy metrics, and sensitivity 193 
analysis (see Data Supplement).  194 
 195 
Results 196 
Development of the Prognostic Signature 197 
 
 
To identify a prognostic signature capable of patient stratification by risk for 198 
regional or distant metastasis from primary cSCC tumors, deep machine learning was 199 
applied to training cohort gene expression data (n=122) (Supplemental Table 1). The 200 
algorithm selected for validation was comprised of two gene expression signatures, 201 
inclusive of 6 control and 34 discriminant genes, with modeling performed using neural 202 
networks. This 40-GEP algorithm generated linear scores for probability of metastasis 203 
from each signature. 204 
Independent Validation of the 40-GEP Prognostic Signature 205 
To validate the prognostic capability of the 40-GEP, the algorithm was applied to 206 
an independent validation cohort comprised of 321 primary cSCC cases (52 with 207 
documented metastasis, and 269 cases without an event) (Table 1). The algorithm 208 
demonstrated a statistically significant ability to stratify metastatic risk. The validated 40-209 
GEP was then used to define risk groups with increasing metastasis risk: Class 1 (low-210 
risk, n=203), Class 2A (high-risk, n=93), and Class 2B (highest-risk, n=25). Significantly 211 
different 3-year MFS rates were observed for Class 1 (91.6%), Class 2A (80.6%), and 212 
Class 2B (44.0%) groups following Kaplan-Meier survival analysis (Figure 2, log-rank 213 
test, p<0.0001). Higher 40-GEP Class was associated with a statistically significant 214 
increase in risk for metastasis and disease-specific death. HRs for metastasis for Class 215 
2A and Class 2B were 2.44 and 10.15 (p<0.01, p<0.0001), and for disease-specific 216 
death were 5.4 and 8.8 (p<0.05, p<0.01), respectively. Of the 13 reported deaths due to 217 
cSCC, 10 were classified as Class 2. 218 
Prognostic Accuracy of the 40-GEP Test Compared to Staging Systems 219 
 
 
The 40-GEP signature was an independent predictor of risk when analyzed in a 220 
bivariable model with AJCC (Class 2A HR=2.15, p=0.021; Class 2B HR=9.55, 221 
p<0.0001) or BWH (Class 2A HR=2.27, p=0.016; Class 2B HR=8.72, p<0.0001) T-stage 222 
(Table 2 and Supplemental Table 2). Multivariable analysis with individual 223 
clinicopathological features also demonstrated independent prognostic value of the 40-224 
GEP signature (Supplemental Table 3). Supplemental Table 4 reports the number of 225 
cases by metastatic outcome, 40-GEP class, and NCCN risk group or T-stage. Cases 226 
with missing clinicopathologic data (n=168, most missing tumor thickness) were staged 227 
in the bivariable analysis with assumption of null values for missing data. Since this may 228 
have resulted in understaging by T-stage or binary T-stage in 34 or 6 cases, 229 
respectively, via BWH, and 164 cases via AJCC, posthoc sensitivity analyses were 230 
performed. These analyses yielded similar effect sizes and significance, demonstrating 231 
the robustness of the primary analysis despite the assumption of null values for missing 232 
data (Supplemental Table 5).  233 
Overall, accuracy metrics for AJCC (low T1/T2 vs. high T3/T4) and BWH (low 234 
T1/T2a vs. high T2b/T3) staging aligned with previously published data (Table 3); 235 
although, the percentages of metastases occurring in low T-stages were higher than 236 
previously reported (62% and 75% for AJCC and BWH stages, respectively).24–27 The 237 
40-GEP Class 2B group demonstrated a PPV of 60% compared to 32.8%, 35.1%, and 238 
16.7% for AJCC, BWH, and NCCN high-risk groups, respectively (Table 3). The Class 1 239 
group was associated with a 91.1% NPV compared with the 87.7%, 86.3%, and 90.5% 240 
NPV for AJCC, BWH, and NCCN, respectively. Likelihood ratios, combining sensitivity 241 
and specificity to indicate probability that metastasis will (+LR) or will not (-LR) occur 242 
 
 
based on Class result, are reported in Table 3. Importantly, 63.0% of the high-risk 243 
NCCN cases were identified as low-risk Class 1 by the 40-GEP. 244 
 245 
Discussion 246 
This study reports the discovery, development, and validation of a 40-GEP test 247 
that classifies cSCC patients into prognostic groups; low-risk for metastasis (Class 1, 248 
91.4% 3-year MFS), and high- and highest-risk for metastasis (Class 2A, 80.6%; and 249 
Class 2B, 44.0% 3-year MFS). The study was designed to include cases with at least 250 
one NCCN high-risk feature to model a high-risk cSCC population (93.5%). This is 251 
reflected in the overall 16.2% rate of regional or distant metastasis, compared with 252 
previously reported rates of <6% for the general cSCC patient population.5, 10, 15   253 
Clinical decision-making has benefitted from development of multi-analyte 254 
algorithmic GEP tests that report metastasis risk independently of clinicopathologic 255 
features. GEP tests currently offered for breast cancer38–40, prostate cancer41, 42, uveal 256 
melanoma43, 44, and cutaneous melanoma45–47 have been shown to help guide 257 
treatment. NCCN guidelines for cSCC recommend that patients with certain high-risk 258 
features consider pre-operative nodal staging, elective nodal surgery, Mohs 259 
micrographic surgery or standard excision with wider margins, adjuvant radiation, or 260 
clinical trial enrollment.3, 48–51 One challenge with clinicopathologic-based guidelines is 261 
that high-risk features are often undetected through initial biopsy and, therefore, often 262 
cannot be used for surgical planning. The 40-GEP can be performed on superficial 263 
biopsies, thus enabling improved surgical decision making using molecular risk 264 
refinement prior to full capture of histopathological features on excisional specimens. In 265 
 
 
addition, as the 40-GEP class results demonstrated prognostic value independent from 266 
staging, this risk assessment may help guide post-operative decision making.52  267 
Contemporary staging systems are limited in accuracy for identifying patients 268 
who are at high risk for developing metastatic disease, as only 24%-38% of patients 269 
with BWH stage T2b/T3 tumors and 14%-17% of AJCC T3/T4 patients develop 270 
metastasis.24–27 NCCN’s expansive definition of high-risk cSCC suffers from a still lower 271 
PPV and risks overtreating patients. While cSCC guidelines recommend considering 272 
specific interventions for patients with high-risk tumors, lack of accurate assessment of 273 
metastatic risk prevents some physicians from confidently selecting nodal staging, 274 
adjuvant therapy, clinical trials, or increased surveillance. Prognostic tools that improve 275 
the ability to identify both low- and high-risk patients within the high-risk cSCC spectrum 276 
would facilitate risk-appropriate reductions in intensity of surveillance and treatment for 277 
patients with low-risk biology, and improved allocation of healthcare resources to high-278 
risk patients. 279 
The 40-GEP test achieved a PPV of 60% for Class 2B tumors, exceeding the 280 
PPV observed for BWH and AJCC systems in this study (35.1% and 32.8%, 281 
respectively); while maintaining comparable accuracy metrics for NPV, sensitivity, and 282 
specificity. The NPV for the 40-GEP test was 91.1% for Class 1 vs. Class 2 tumors, 283 
which was comparable to NCCN and 5% higher than BWH and AJCC. Likelihood ratios 284 
show that a Class 2B result is associated with significantly increased probability for 285 
metastasis and a Class 1 result with lower probability. Thus, incorporation of a Class 1 286 
result for clinically-defined high-risk tumors could identify a substantial group of patients 287 
with biologically low-risk tumors who could be considered for de-escalation of 288 
 
 
management, potentially ruling out adjuvant treatment plans and nodal surgical staging. 289 
On the other hand, a Class 2B result could identify a group of patients who may benefit 290 
from adjuvant interventions and surveillance. 291 
Descriptive molecular characterization of cSCC has previously identified genes 292 
involved in disease pathogenesis.53–56 Studies comparing specimens from various 293 
stages of progression (e.g., in situ to invasive cSCC) have reported differential 294 
expression of various genes and miRNAs.30, 57–67 However, few studies of prognostic 295 
biomarkers from primary tumors have been reported.68, 69 Many of the discriminant 296 
genes comprising the 40-GEP algorithm (Supplemental Table 6) have been previously 297 
reported in cSCC and/or have known functions in cancer-relevant pathways. Some 298 
genes in the 40-GEP signature do not have an established role in cSCC biology, but 299 
future studies have potential to identify how these genes promote cSCC metastasis. 300 
As with all archival studies, there is possible bias in specimen collection based 301 
on availability of tissue and adherence to protocol inclusion/exclusion criteria. This may 302 
account for the high fraction of metastases occurring in cases that were low-stage by 303 
BWH and AJCC criteria. Since not all histological features used for staging are 304 
consistently reported in pathology and Mohs reports, cases may be understaged. To 305 
address this problem, all specimens underwent central pathology review and restaging 306 
according to contemporary staging criteria with medical records reviewed for any 307 
additional high-risk features. Because cases excised via Mohs generally have no tissue 308 
available for review other than the shave biopsy, under-reporting of high-stage features 309 
and understaging may result if features were not reported in surgical notes or if a 310 
surgical report was not available for review. The low sensitivities of AJCC and BWH 311 
 
 
staging reported herein relative to other cohorts (39% and 25%, respectively, versus 312 
78% and 73% recently reported24) are reflective of the high fraction of metastases 313 
occurring in low-stage cases in the present cohort, potentially a result of understaging. 314 
However, sensitivity analysis supported that missing features had negligible impact on 315 
the prognostic capacity of the 40-GEP. Additional multi-center cohort studies in target 316 
populations for 40-GEP testing should be undertaken to confirm the PPVs and NPVs 317 
reported herein, and to determine to what degree they are reflective of the high-risk 318 
cSCC population. However, the 16% metastasis rate of the present NCCN high-risk 319 
validation cohort, as well as AJCC and BWH PPVs that were comparable to prior 320 
studies, indicate a likelihood of high reliability for the 40-GEP.   321 
As cSCC poses a significant burden on the healthcare system with increasing 322 
morbidity and mortality, it is essential to identify which patients warrant additional 323 
surveillance and therapeutic interventions and which are low risk and, thus, could avoid 324 
unnecessary procedures. Staging systems based on clinicopathological features alone 325 
are limited in their ability to accurately stratify patients, primarily due to low PPV. The 326 
40-GEP demonstrated a PPV of 60% in the present study, the highest reported to date 327 
for cSCC; thus, identifying a patient group with a 60% risk for metastasis. Coupling 328 
clinicopathological features with tumor-intrinsic risk, as per the 40-GEP prognostic test 329 
developed and validated herein, has potential to improve patient outcomes, quality of 330 
life, and appropriate allocation of healthcare resources for cSCC patients.  331 
 332 
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Figure Legends 558 
Figure 1. Cutaneous Squamous Cell Carcinoma. Study cohorts: tissue samples and 559 
associated data acquisition. CRF, case report form; f/u, follow-up; event, regional or 560 
distant metastasis; QC, quality control. Protocol and monitoring are ongoing, 561 
assessment performed Oct. 1, 2019. To ensure proper classification, the training set 562 
was restricted to cases with a documented metastatic event or at least 4 years of follow-563 
up. Cases not included in this report will be used for a second validation cohort. QC 564 
criteria were different between discovery and validation assays.  565 
 566 
Figure 2. Cutaneous Squamous Cell Carcinoma. Kaplan-Meier analysis of the 40-GEP 567 
prognostic test and outcomes from independent validation of cutaneous cSCC cases 568 
(n=321). 569 




Table 1: Demographics and clinical characteristics of validation cohort (n=321) 572 
Feature All  (n=321) 
Non Met  
(n=269) 
Regional/distant met 
(n=52) p value 
Age:  
Median years (range) 
70 (34-95) 70 (34-95) 72 (44-90) 0.84 
Male sex  235 (73.2%) 191 (71.0%) 44 (84.6%) 0.042 
Caucasian 320 (99.7%) 269 (100%) 51 (98.1%) 0.16 
Non-Hispanic* 312 (97.2%) 262 (97.4%) 50 (96.2%) 0.62 
Immune deficient** 76 (23.7%) 59  (21.9%) 17 (32.7%) 0.10 
Prior Hx of SCC 135 (42.1%) 109 (40.5%) 26 (50.0%) 0.22 
Located on H&N 214 (66.7%) 171 (63.6%) 43 (82.7%) 0.007 
Tumor diameter:  
Mean cm (StDev)*** 1.8 (+/-1.9) 1.6 (+/-1.8) 2.8 (+/-2.4) <0.0001 
Tumor thickness:  
Mean mm (StDev)# 
3.9 (+/-6.4) 3.4 (+/-6.6) 7.2 (+/-3.6) <0.0001 
Poorly differentiated 36 (11.2%) 22 (8.2%) 14 (26.9%) <0.0001 
Clark Level IV / V 62 (19.3%) 49 (18.2%) 13 (25.0%) <0.0001 
PNI## 
   present (≥0.1mm) 7 (2.2%) 5 (1.9%) 2 (3.9%) 
<0.0001    present (<0.1mm or     
   unknown caliper) 29 (9.0%) 16 (6.0%) 13 (25%) 
   not present 285 (88.8%) 248 (92.2%) 37 (71.2%) 
Invasion into fat 43  (13.4%) 28 (10.4%) 15 (28.9%) 0.0004 
Definitive surgery MMS### 256 (79.8%) 222 (82.5%) 34 (65.4%) 0.032 
AJCC8 T Stage 
     T1 201 (62.6%) 175 (65.1%) 26 (50%) 
0.001 
     T2 59 (18.4%) 53 (19.7%) 6 (11.5%) 
     T3 54 (16.8%) 36 (13.4%) 18 (34.6%) 
     T4 7 (2.2%) 5  (1.9%) 2 (3.9%) 
BWH T Stage 
     T1 186 (57.9%) 166 (61.7%) 20 (38.5%) 
0.0004 
     T2a 98 (30.5%) 79 (29.4%) 19 (36.5%) 
     T2b 30 (9.4%) 19 (7.1%) 11 (21.2%) 
     T3 7 (2.2%) 5 (1.9%) 2 (3.9%) 
NCCN High risk 300 (93.5%) 250 (92.9%) 50 (96.2%) 0.39 
 
 
NOTE. Data analyzed using Chi-square test or Kruskal-Wallis F test. 
Abbreviations: Hx, history; SCC, squamous cell carcinoma; H&N, head and neck; StDev, standard deviation; PNI, 
perineural invasion; MMS, Mohs micrographic surgery; AJCC8, American Joint Committee on Cancer, Cancer 
Staging Manual, Eighth Edition; BWH, Brigham and Women’s Hospital; NCCN, National Comprehensive Cancer 
Network. *One patient did not report ethnicity. **67 of 76 immune deficient patients were organ transplant recipients. 
***Tumor diameter reported (n=295). #Tumor thickness reported (n=115). ##PNI with nerve caliper ≥0.1mm or in 
nerve deeper than the dermis are upstaging factors for AJCC. Only nerve caliper ≥0.1mm is an upstaging factor for 
BWH. 1 of 7 cases met AJCC upstaging but not BWH upstaging.  ###Mohs or wide local excision (n=319) with 2 
cases not having additional surgery beyond biopsy. 
 573 
Table 2. Multivariate Cox regression analyses of risk for metastasis in 40-GEP validation cases 574 
(n=321) with binary AJCC and BWH T stage 575 
Multivariate Cox Regression 
n=321 (52 events) HR (95% CI) p value 
 40-GEP 
  
        Class 1 1.0 --- 
        Class 2A 2.15 (1.12-4.12) 0.021 
        Class 2B 9.55 (4.79-19.06) <0.0001 
 AJCC8   
        T1/T2 1.0 --- 
        T3/T4 2.68 (1.52-4.72) <0.001 
  40-GEP   
        Class 1 1.0 --- 
        Class 2A 2.27 (1.19-4.35) 0.013 
        Class 2B 8.72 (4.30-17.71) <0.0001 
 BWH 
  
        T1/T2a 1.0 --- 
        T2b/T3 2.03  (1.07-3.88) 0.032 
NOTE. An event was regional or distant metastasis. 
Abbreviations: HR, hazard ratio; CI, confidence interval; GEP, 
gene expression profile; AJCC8, American Joint Committee on 
Cancer, Cancer Staging Manual, Eighth Edition; BWH, Brigham 
























(Class 2B v 1/2A) 
40-GEP 
(Class 2 v 1) 
AJCC 8* 





(High v low) 
Sensitivity 28.8% 65.4% 38.5% 25.0% 96.2% 
Specificity 96.3% 68.8% 84.8% 91.1% 7.1% 
+LR 7.78 2.10 2.53 2.81 1.04 
-LR 0.74 0.50 0.73 0.82 0.54 
PPV 60.0% 28.8% 32.8% 35.1% 16.7% 
NPV 87.5% 91.1% 87.7% 86.3% 90.5% 
Abbreviations: GEP, gene expression profile; AJCC8, American Joint Committee on Cancer, Cancer 
Staging Manual, Eighth Edition; BWH, Brigham and Women’s Hospital; NCCN, National Comprehensive 
Cancer Network; LR, likelihood ratio; PPV, positive predictive value; NPV, negative predictive value. 
*Missing histopathologic information was treated as negative. 
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